ALKS

AlkermesA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

Current thesis

The bull case is that Alkermes is evolving from a legacy CNS-commercial story into a sleep-medicine platform with LUMRYZ cash generation plus alixorexton optionality; Q1 2026 also showed strong proprietary product sales growth and management framed the orexin category as a large opportunity [#SEC-8K-2026-05-05].

Posture

Constructive

Lead driver

Momentum

What changed

Momentum remains the lead driver in the composite, 7D delta -2.5.

What can break

Clinical and regulatory risk if Brilliance phase 3 narcolepsy studies fail to confirm the phase 2 alixorexton profile.

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $50.00 · Bull $61.00 · Bear $41.00

Data freshness

Prices

As of 2026-07-18

Fundamentals

As of 2026-07-17 • Vendor: Data Vendor v1

Scores

As of 2026-07-18 • Model: HYBRID_IC_RP

AI Memo

As of 2026-07-07 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-18

Supporting evidence

What

Grade A · Constructive

Confidence Medium · Net Neutral

Target $51.59

Why

Momentum92 · Δ7d -2.5

Value61 · Δ7d -0.3

Sentiment40 · Δ7d -4.4

So what

Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Lead driver: Momentum · See technicals

Momentum

26% active weight

Current posture

7d trendFlat

Δ7d

-2.5

Δ21d

-3.1

Value

39% active weight

Current posture

7d trendFlat

Δ7d

-0.3

Δ21d

+0.1

Sentiment

34% active weight

Current posture

7d trendSoftening

Δ7d

-4.4

Δ21d

+10.2

Why this grade

Composite grade A. Momentum 92.3 / Value 61.1 / Sentiment 40.1

Fundamentals (TTM)

As of 2026-07-17

Market Cap

$8.79B

Beta

0.44

Shares Out

166.68M

P/E (TTM)

13.9

P/S (TTM)

3.04

P/FCF (TTM)

9.42

Rev YoY

+28.2%

EPS YoY

-400.5%

Gross Margin

+85.5%

Op Margin

+23.6%

Net Debt

-$1.25B

Current Ratio

2.27

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology